Home › Epidermolysis Bullosa Dystrophica › NCT06423573

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

A Long-term Non-interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez

Who can join

All ages · All sexes

Inclusion Criteria:

* Patients with a confirmed diagnosis of dystrophic EB or junctional EB

Exclusion Criteria:

* None

About the study

In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for a minimum of 3 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.

What is being tested

• Filsuvez (drug)

Sponsor: Chiesi Farmaceutici S.p.A. · Participants: 170 · Started: Dec 18, 2024

Contact the study team

• Chiesi Clinical Trials · Phone: +3905212791

Official record on ClinicalTrials.gov — NCT06423573

Locations in the U.S.

Conditions

• Epidermolysis Bullosa Dystrophica

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.